Clinical Trials
11 trialsNCT07572136 2026-06-05
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Institutes of Health Clinical Center (CC)
Phase 1 Not yet recruiting
NCT07614022 2026-06-05
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
Wake Forest University Health Sciences
Phase 1 Not yet recruiting
NCT07616089 2026-05-29
FXS0683-001
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1 Not yet recruiting
NCT07573111 2026-05-13
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Laguna Biotherapeutics, Inc.
Phase 1 Not yet recruiting
NCT07283640 2026-05-05
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07565220 2026-05-04
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
University of Pittsburgh
Phase 1 Not yet recruiting
NCT07518654 2026-04-08
ThINKK-01
St. Justine's Hospital
Phase 1 Not yet recruiting
NCT07254793 2026-04-07
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
University of Arizona
Phase 1 Not yet recruiting
NCT07166549 2025-12-24
BaseCAR-01
University Hospital, Basel, Switzerland
Phase 1 Not yet recruiting
NCT06894693 2025-03-25
A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies
Guangdong Ruishun Biotech Co., Ltd
Phase 1 Not yet recruiting
NCT06641024 2024-10-15
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
Chongqing Precision Biotech Co., Ltd
Phase 1 Not yet recruiting